



## Areas of Expertise

- Preclinical drug development including non-clinical pharmacology, pharmacokinetics and toxicology for new medicinal products
- Biopharmaceuticals including gene and cellular therapies
- Mechanistic safety
- Regulatory strategies for biological products and emerging technologies

## Major projects

### As Regulator

- 1992-2012 Preclinical expert and member of the Board of Medicines of the Portuguese Medicines Agency (Infarmed)
- 1993-2012 CPMP/CHMP member, EMA
- 1996-2000 SWP member, EMA
- 2000-2012 Chair of SWP, EMA
- 2000-2012 SAWP member, EMA
- 2008-2012 CAT member, EMA
- 2007-2012: Co-deputy representing the European Commission on the ICH Expert Working Groups for M3 (R2), S6 (R1) and S1
- 2007: CHMP Rapporteur on the guideline addressing risk mitigation for First in Human clinical studies

### As Academic

- Since 2010- Advisory Board of the IMI granted research projects, Safe-T, PANOPTES and stemBANCC
- Co-Responsible for module 2.2. on Regulatory Guidelines of the IMI training project SafeSciMet
- Since 2011- member of the stem cell working group of the European Partnership for animal alternatives (EPAA)
- Since 2012- member of the UK NC3Rs (Nonclinical replacement, reduction and refinement of animal in research) group.
- 2009 and 2012 integrated the panel of Reviewers of the FP7 research Grant Applications on Preclinical Development of Orphan Diseases.

## Associations

Portuguese College of Pharmacists, Specialist on Regulatory Affairs, Portuguese Society of Pharmacology (member of IUPHAR), EUFEPS, DIA, ETS, New York Academy of Sciences

## **Publications**

Publications / Conferences on basic science and nonclinical safety regulatory science aspects, including e.g. mechanisms of non-genotoxic carcinogenesis, Advanced Therapy medicinal products and Biomarkers.

The complete list can be provided upon request.